Browsing by Publisher "Mosby Inc."

Now showing 1 - 8 of 8
  • No Thumbnail Available
    Item
    Injury to the lacrimal apparatus after endoscopic sinus surgery: Surgical implications from active transport dacryocystography
    (Mosby Inc., 2001) Unlu H.H.; Goktan C.; Aslan A.; Tarhan S.
    In order to evaluate the lacrimal drainage system injury after functional endoscopic sinus surgery, surgical records and postoperative active transport dacryocystography imaging of 31 patients were analyzed. Presence of the lacrimal bone dehiscence and no passage of the contrast material into the inferior meatus were noted as the signs of injury to the lacrimal canal on active transport dacryocystography. Bony dehiscence was detected in 53.2% of the operated sides but 20% of the nonoperated sides. No passage of the contrast material into the inferior meatus was observed in 14.9% of the operated sides. There were no cases of epiphora postoperatively. The lacrimal drainage system injury was more frequently observed on the left sides operated. We conclude that lacrimal drainage system injury might occur in various extents during functional endoscopic sinus surgery. However, it does not necessarily result in postoperative epiphora. Performing the middle meatal antrostomy in posteroinferior direction, and uncinectomy with backbiting forceps or a shaver might help in reducing the lacrimal injury. Active transport dacryocystography can be adopted as an alternative diagnostic tool in detection of the lacrimal injury.
  • No Thumbnail Available
    Item
    Nurses' knowledge regarding patients with intravenous catheters and phlebitis interventions
    (Mosby Inc., 2003) Karadeniz G.; Kutlu N.; Tatlisumak E.; Özbakkaloǧlu B.
    This study was planned and applied in 2 stages. Stage I was applied to determine the knowledge of nurses working in the internal medicine, surgery, obstetrics and gynecology, pediatrics, and other services in Celal Bayar University Hospital about using intravenous catheter and intravenous fluid treatment, and the symptoms and treatment procedure for phlebitis. Stage II consisted of observation of all patients who had intravenous catheters for symptoms of phlebitis for 5 days and the interventions the nurses used for the patients who had phlebitis. In stage I, questionnaires were used to determine the knowledge of the nurses; in stage II, 2 investigators observed the patients. Results were evaluated using SPSS software with χ2 statistical analysis. Nurses were found to have high knowledge levels, but their practices were not suitable to their knowledge levels. Of the patients who participated in the study, 67.24% showed symptoms of phlebitis. We found that there was a significant relationship (P < .05) between the selection of the vein and the occurrence of phlebitis in patients who had an intravenous catheter. We also found that the relationships between the age groups of the patients and phlebitis and the relationships between the diagnosis and phlebitis were statistically significant (P < .05).
  • No Thumbnail Available
    Item
    Adhesive tape technique to enhance potassium hydroxide diagnosis of occult fungal infections
    (Mosby Inc., 2014) Sahin M.T.; Maibach H.I.
    [No abstract available]
  • No Thumbnail Available
    Item
    MACVIA clinical decision algorithm in adolescents and adults with allergic rhinitis
    (Mosby Inc., 2016) Bousquet J.; Schünemann H.J.; Hellings P.W.; Arnavielhe S.; Bachert C.; Bedbrook A.; Bergmann K.-C.; Bosnic-Anticevich S.; Brozek J.; Calderon M.; Canonica G.W.; Casale T.B.; Chavannes N.H.; Cox L.; Chrystyn H.; Cruz A.A.; Dahl R.; De Carlo G.; Demoly P.; Devillier P.; Dray G.; Fletcher M.; Fokkens W.J.; Fonseca J.; Gonzalez-Diaz S.N.; Grouse L.; Keil T.; Kuna P.; Larenas-Linnemann D.; Lodrup Carlsen K.C.; Meltzer E.O.; Mullol J.; Muraro A.; Naclerio R.N.; Palkonen S.; Papadopoulos N.G.; Passalacqua G.; Price D.; Ryan D.; Samolinski B.; Scadding G.K.; Sheikh A.; Spertini F.; Valiulis A.; Valovirta E.; Walker S.; Wickman M.; Yorgancioglu A.; Haahtela T.; Zuberbier T.; Aberer W.; Adachi M.; Agache I.; Akdis C.; Akdis M.; Annesi-Maesano I.; Ansotegui I.J.; Anto J.M.; Arshad S.H.; Baiardini I.; Baigenzhin A.K.; Barbara C.; Bateman E.D.; Beghé B.; Bel E.H.; Ben Kheder A.; Bennoor K.S.; Benson M.; Bernstein D.; Michael B.; Thomas B.; Bindslev-Jensen C.; Bjermer L.; Blain H.; Boner A.; Bonini M.; Bonini S.; Bosse I.; Bouchard J.; Boulet L.-P.; Bourret R.A.; Bousquet P.J.; Braido F.; Briggs A.H.; Brightling C.E.; Buhl R.; Burney P.; Bush A.; Caballero-Fonseca F.; Caimmi D.P.; Camargos P.; Camuzat T.; Carlsen K.-H.; Carr W.; Sarabia A.C.; Chatzi L.; Chen Y.; Chiron R.; Chkhartishvili E.; Chuchalin A.; Ciprandi G.; Cirule I.; Correia de Sousa J.; Costa D.; Crooks G.; Custovic A.; Dahlen S.-E.; Darsow U.; De Blay F.; De Manuel Keenoy E.; Dedeu T.; Deleanu D.; Denburg J.; Didier A.; Dinh-Xuan A.-T.; Dokic D.; Douagui H.B.; Dubakiene R.; Durham S.; Dykewicz M.; El-Gamal Y.; Emuzyte R.; Fink-Wagner A.; Fiocchi A.; Forastiere F.; Gamkrelidze A.; Gemicioğlu B.; Gereda J.E.; Gerth van Wijk R.; Gotua M.; Grisle I.; Guzmán M.A.; Heinrich J.; Hellquist-Dahl B.; Horak F.; Howarth P.H.; Humbert M.; Hyland M.; Ivancevich J.-C.; Jares E.J.; Johnston S.L.; Jonquet O.; Joos G.; Jung K.-S.; Just J.; Jutel M.; Kaidashev I.P.; Khaitov M.; Kalayci O.; Kalyoncu F.; Keith P.; Khaltaev N.; Kleine-Tebbe J.; Klimek L.; N'Goran B.K.; Kolek V.; Koppelman G.H.; Kowalski M.; Kull I.; Kvedariene V.; Lambrecht B.; Lau S.; Laune D.; Le Thi Tuyet L.; Li J.; Lieberman P.; Lipworth B.J.; Renaud L.; Magard Y.; Magnan A.; Mahboub B.; Majer I.; Makela M.; Manning P.J.; Masjedi M.R.; Maurer M.; Mavale-Manuel S.; Melén E.; Melo-Gomes E.; Mercier J.; Merk H.; Miculinic N.; Mihaltan F.; Milenkovic B.; Mohammad Y.; Molimard M.; Momas I.; Montilla-Santana A.; Morais-Almeida M.; Mösges R.; Nadif R.; Namazova-Baranova L.; Neffen H.; Nekam K.; Neou A.; Niggemann B.; Nyembue D.; O'Hehir R.; Ohta K.; Okamoto Y.; Okubo K.; Ouedraogo S.; Paggiaro P.-L.; Pali-Schöll I.; Palmer S.; Panzner P.; Papi A.; Park H.-S.; Pavord I.; Pawankar R.; Pfaar O.; Picard R.; Pigearias B.; Pin I.; Plavec D.; Pohl W.; Popov T.; Postma D.S.; Potter P.; Poulsen L.K.; Rabe K.F.; Raciborski F.; Pontal F.R.; Reitamo S.; Repka-Ramirez M.-S.; Robalo-Cordeiro C.; Roberts G.; Rodenas F.; Rolland C.; Rodriguez M.R.; Romano A.; Rosado-Pinto J.; Rosario N.A.; Rosenwasser L.; Rottem M.; Sanchez-Borges M.; Sastre-Dominguez J.; Schmid-Grendelmeier P.; Serrano E.; Simons F.E.R.; Sisul J.-C.; Skrindo I.; Smit H.A.; Solé D.; Sooronbaev T.; Spranger O.; Stelmach R.; Strandberg T.; Sunyer J.; Thijs C.; Todo-Bom A.-M.; Triggiani M.; Valenta R.; Valero A.L.; van Hage M.; Vandenplas O.; Vezzani G.; Vichyanond P.; Viegi G.; Wagenmann M.; Wahn U.; De Yun W.; Williams D.; Wright J.; Yawn B.P.; Yiallouros P.; Yusuf O.M.; Zar H.J.; Zernotti M.; Zhang L.; Zhong N.; Zidarn M.
    The selection of pharmacotherapy for patients with allergic rhinitis (AR) depends on several factors, including age, prominent symptoms, symptom severity, control of AR, patient preferences, and cost. Allergen exposure and the resulting symptoms vary, and treatment adjustment is required. Clinical decision support systems (CDSSs) might be beneficial for the assessment of disease control. CDSSs should be based on the best evidence and algorithms to aid patients and health care professionals to jointly determine treatment and its step-up or step-down strategy depending on AR control. Contre les MAladies Chroniques pour un VIeillissement Actif en Languedoc-Roussillon (MACVIA-LR [fighting chronic diseases for active and healthy ageing]), one of the reference sites of the European Innovation Partnership on Active and Healthy Ageing, has initiated an allergy sentinel network (the MACVIA-ARIA Sentinel Network). A CDSS is currently being developed to optimize AR control. An algorithm developed by consensus is presented in this article. This algorithm should be confirmed by appropriate trials. © 2016 The Authors
  • No Thumbnail Available
    Item
    Allergic Rhinitis and its Impact on Asthma (ARIA) Phase 4 (2018): Change management in allergic rhinitis and asthma multimorbidity using mobile technology
    (Mosby Inc., 2019) Bousquet J.; Hellings P.W.; Agache I.; Amat F.; Annesi-Maesano I.; Ansotegui I.J.; Anto J.M.; Bachert C.; Bateman E.D.; Bedbrook A.; Bennoor K.; Bewick M.; Bindslev-Jensen C.; Bosnic-Anticevich S.; Bosse I.; Brozek J.; Brussino L.; Canonica G.W.; Cardona V.; Casale T.; Cepeda Sarabia A.M.; Chavannes N.H.; Cecchi L.; Correia de Sousa J.; Costa E.; Cruz A.A.; Czarlewski W.; De Carlo G.; De Feo G.; Demoly P.; Devillier P.; Dykewicz M.S.; El-Gamal Y.; Eller E.E.; Fonseca J.A.; Fontaine J.-F.; Fokkens W.J.; Guzmán M.-A.; Haahtela T.; Illario M.; Ivancevich J.-C.; Just J.; Kaidashev I.; Khaitov M.; Kalayci O.; Keil T.; Klimek L.; Kowalski M.L.; Kuna P.; Kvedariene V.; Larenas-Linnemann D.; Laune D.; Le L.T.T.; Carlsen K.L.; Lourenço O.; Mahboub B.; Mair A.; Menditto E.; Milenkovic B.; Morais-Almeida M.; Mösges R.; Mullol J.; Murray R.; Naclerio R.; Namazova-Baranova L.; Novellino E.; O'Hehir R.E.; Ohta K.; Okamoto Y.; Okubo K.; Onorato G.L.; Palkonen S.; Panzner P.; Papadopoulos N.G.; Park H.-S.; Paulino E.; Pawankar R.; Pfaar O.; Plavec D.; Popov T.A.; Potter P.; Prokopakis E.P.; Rottem M.; Ryan D.; Salimäki J.; Samolinski B.; Sanchez-Borges M.; Schunemann H.J.; Sheikh A.; Sisul J.-C.; Rajabian-Söderlund R.; Sooronbaev T.; Stellato C.; To T.; Todo-Bom A.-M.; Tomazic P.-V.; Toppila-Salmi S.; Valero A.; Valiulis A.; Valovirta E.; Ventura M.-T.; Wagenmann M.; Wang D.Y.; Wallace D.; Waserman S.; Wickman M.; Yorgancioglu A.; Zhang L.; Zhong N.; Zidarn M.; Zuberbier T.; Aberer W.; Akdis C.A.; Akdis M.; Alberti M.R.; Almeida R.; Angles R.; Arnavielle S.; Asayag E.; Asarnoj A.; Arshad H.; Avolio F.; Bacci E.; Baiardini I.; Barbara C.; Barbagallo M.; Baroni I.; Barreto B.A.; Basagana X.; Bedolla-Barajas M.; Beghé B.; Bel E.H.; Bergmann K.C.; Benson M.; Bertorello L.; Białoszewski A.Z.; Bieber T.; Bialek S.; Bjermer L.; Blain H.; Blasi F.; Blua A.; Bochenska Marciniak M.; Bogus-Buczynska I.; Boner A.L.; Bonini M.; Bonini S.; Bouchard J.; Boulet L.P.; Bourret R.; Braido F.; Briedis V.; Brightling C.E.; Bucca C.; Buhl R.; Buonaiuto R.; Panaitescu C.; Burguete Cabañas M.T.; Burte E.; Bush A.; Caballero-Fonseca F.; Caillot D.; Caimmi D.; Calderon M.A.; Camargos P.A.M.; Camuzat T.; Canfora G.; Carreiro-Martins P.; Carriazo A.M.; Carr W.; Cartier C.; Castellano G.; Chen Y.; Chiron R.; Chivato T.; Chkhartishvili E.; Chuchalin A.G.; Chung K.F.; Ciaravolo M.M.; Ciceran A.; Cingi C.; Ciprandi G.; Carvalho Coehlo A.C.; Colas L.; Colgan E.; Coll J.; Conforti D.; Cortés-Grimaldo R.M.; Corti F.; Costa-Dominguez M.C.; Courbis A.L.; Cox L.; Crescenzo M.; Custovic A.; Dahlen S.E.; Dario C.; da Silva J.; Dauvilliers Y.; Darsow U.; De Blay F.; Dedeu T.; de Fátima Emerson M.; De Vries G.; De Martino B.; de Paula Motta Rubini N.; Deleanu D.; Denburg J.A.; Di Capua Ercolano S.; Di Carluccio N.; Didier A.; Dokic D.; Dominguez-Silva M.G.; Douagui H.; Dray G.; Dubakiene R.; Durham S.R.; Du Toit G.; Eklund P.; Emuzyte R.; Farrell J.; Farsi A.; Ferreira de Mello J.; Ferrero J.; Fink-Wagner A.; Fiocchi A.; Forti S.; Fuentes-Perez J.M.; Gálvez-Romero J.L.; Gamkrelidze A.; Garcia-Aymerich J.; García-Cobas C.Y.; Garcia-Cruz M.H.; Gemicioğlu B.; Genova S.; George C.; Gereda J.E.; Gerth van Wijk R.; Gomez R.M.; Gómez-Vera J.; González Diaz S.; Gotua M.; Grisle I.; Guidacci M.; Guldemond N.A.; Gutter Z.; Hajjam J.; Hernández L.; Hourihane J.O.; Huerta-Villalobos Y.R.; Humbert M.; Iaccarino G.; Jares E.J.; Jassem E.; Johnston S.L.; Joos G.; Jung K.S.; Jutel M.; Kalyoncu A.F.; Karjalainen J.; Kardas P.; Keith P.K.; Khaltaev N.; Kleine-Tebbe J.; Kuitunen M.; Kull I.; Kupczyk M.; Krzych-Fałta E.; Lacwik P.; Lauri D.; Lavrut J.; Lessa M.; Levato G.; Li J.; Lieberman P.; Lipiec A.; Lipworth B.; Lodrup Carlsen K.C.; Louis R.; Luna-Pech J.A.; Maciej K.; Magnan A.; Maier D.; Majer I.; Malva J.; Mandajieva E.; Manning P.; De Manuel Keenoy E.; Marshall G.D.; Masjedi M.R.; Maspero J.F.; Mathieu-Dupas E.; Matta Campos J.J.; Matos A.L.; Maurer M.; Mavale-Manuel S.; Mayora O.; Medina-Avalos M.A.; Melén E.; Melo-Gomes E.; Meltzer E.O.; Mercier J.; Miculinic N.; Mihaltan F.; Moda G.; Mogica-Martinez M.D.; Mohammad Y.; Momas I.; Montefort S.; Monti R.; Mora Bogado D.; Morato-Castro F.F.; Mota-Pinto A.; Moura Santo P.; Münter L.; Muraro A.; Nadif R.; Nalin M.; Napoli L.; Neffen H.; Niedeberger V.; Nekam K.; Neou A.; Nieto A.; Nogueira-Silva L.; Nogues M.; Nyembue T.D.; Odzhakova C.; Ortega Cisneros M.; Ouedraogo S.; Pali-Schöll I.; Papi A.; Passalacqua G.; Pedersen S.; Pépin J.L.; Pereira A.M.; Persico M.; Phillips J.; Picard R.; Pigearias B.; Pin I.; Pitsios C.; Pohl W.; Portejoie F.; Pozzi A.C.; Price D.; Puy R.; Pugin B.; Pulido Ross R.E.; Przemecka M.; Rabe K.F.; Raciborski F.; Reitsma S.; Ribeirinho I.; Rimmer J.; Rivero-Yeverino D.; Rizzo J.A.; Rizzo M.C.; Robalo-Cordeiro C.; Rodenas F.; Rodo X.; Rodriguez Gonzalez M.; Rodriguez-Mañas L.; Rolland C.; Rodrigues Valle S.; Roman Rodriguez M.; Romano A.; Rodriguez-Zagal E.; Rolla G.; Roller-Wirnsberger R.E.; Romano M.; Rosado-Pinto J.; Rosario N.; Sagara H.; Sastre-Dominguez J.; Scadding G.K.; Scichilone N.; Schmid-Grendelmeier P.; Serpa F.S.; Shamai S.; Sierra M.; Simons F.E.R.; Siroux V.; Skrindo I.; Solé D.; Somekh D.; Sondermann M.; Sova M.; Sorensen M.; Sorlini M.; Spranger O.; Stelmach R.; Stukas R.; Sunyer J.; Strozek J.; Szylling A.; Tebyriçá J.N.; Thibaudon M.; Trama U.; Triggiani M.; Suppli Ulrik C.; Urrutia-Pereira M.; Valenta R.; van Eerd M.; van Ganse E.; van Hague M.; Vandenplas O.; Vezzani G.; Vasankari T.; Vatrella A.; Verissimo M.T.; Viart F.; Viegi M.; Vicheva D.; Vontetsianos T.; Walker S.; Werfel T.; Westman M.; Williams D.M.; Williams S.; Wilson N.; Wright J.; Wroczynski P.; Yakovliev P.; Yawn B.P.; Yiallouros P.K.; Yusuf O.M.; Zar H.J.; Zernotti M.E.; Zubrinich C.; Zurkuhlen A.
    Allergic Rhinitis and its Impact on Asthma (ARIA) has evolved from a guideline by using the best approach to integrated care pathways using mobile technology in patients with allergic rhinitis (AR) and asthma multimorbidity. The proposed next phase of ARIA is change management, with the aim of providing an active and healthy life to patients with rhinitis and to those with asthma multimorbidity across the lifecycle irrespective of their sex or socioeconomic status to reduce health and social inequities incurred by the disease. ARIA has followed the 8-step model of Kotter to assess and implement the effect of rhinitis on asthma multimorbidity and to propose multimorbid guidelines. A second change management strategy is proposed by ARIA Phase 4 to increase self-medication and shared decision making in rhinitis and asthma multimorbidity. An innovation of ARIA has been the development and validation of information technology evidence-based tools (Mobile Airways Sentinel Network [MASK]) that can inform patient decisions on the basis of a self-care plan proposed by the health care professional. © 2018 American Academy of Allergy, Asthma & Immunology
  • No Thumbnail Available
    Item
    Mobile technology offers novel insights into the control and treatment of allergic rhinitis: The MASK study
    (Mosby Inc., 2019) Bédard A.; Basagaña X.; Anto J.M.; Garcia-Aymerich J.; Devillier P.; Arnavielhe S.; Bedbrook A.; Onorato G.L.; Czarlewski W.; Murray R.; Almeida R.; Fonseca J.; Costa E.; Malva J.; Morais-Almeida M.; Pereira A.M.; Todo-Bom A.; Menditto E.; Stellato C.; Ventura M.T.; Cruz A.A.; Stelmach R.; da Silva J.; Larenas-Linnemann D.; Fuentes-Pérez J.M.; Huerta-Villalobos Y.R.; Emuzyte R.; Kvedariene V.; Valiulis A.; Kuna P.; Samolinski B.; Klimek L.; Mösges R.; Pfaar O.; Shamai S.; Annesi-Maesano I.; Bosse I.; Demoly P.; Fontaine J.-F.; Cardona V.; Mullol J.; Valero A.; Roller-Wirnsberger R.E.; Tomazic P.V.; Chavannes N.H.; Fokkens W.J.; Reitsma S.; Bewick M.; Ryan D.; Sheikh A.; Haahtela T.; Toppila-Salmi S.; Valovirta E.; Makris M.; Papadopoulos N.G.; Prokopakis E.P.; Psarros F.; Cingi C.; Gemicioğlu B.; Yorgancioglu A.; Bosnic-Anticevich S.; O'Hehir R.E.; Bachert C.; Hellings P.W.; Pugin B.; Bindslev-Jensen C.; Eller E.; Kull I.; Melén E.; Wickman M.; De Vries G.; van Eerd M.; Agache I.; Ansotegui I.J.; Dykewicz M.S.; Casale T.; Wallace D.; Waserman S.; Laune D.; Bousquet J.
    Background: Mobile health can be used to generate innovative insights into optimizing treatment to improve allergic rhinitis (AR) control. Objectives: A cross-sectional real-world observational study was undertaken in 22 countries to complement a pilot study and provide novel information on medication use, disease control, and work productivity in the everyday life of patients with AR. Methods: A mobile phone app (Allergy Diary, which is freely available on Google Play and Apple stores) was used to collect the data of daily visual analogue scale (VAS) scores for (1) overall allergic symptoms; (2) nasal, ocular, and asthma symptoms; (3) work; and (4) medication use by using a treatment scroll list including all allergy medications (prescribed and over-the-counter) customized for 22 countries. The 4 most common intranasal medications containing intranasal corticosteroids and 8 oral H1-antihistamines were studied. Results: Nine thousand one hundred twenty-two users filled in 112,054 days of VASs in 2016 and 2017. Assessment of days was informative. Control of days with rhinitis differed between no (best control), single (good control for intranasal corticosteroid–treated days), or multiple (worst control) treatments. Users with the worst control increased the range of treatments being used. The same trend was found for asthma, eye symptoms, and work productivity. Differences between oral H1-antihistamines were found. Conclusions: This study confirms the usefulness of the Allergy Diary in accessing and assessing behavior in patients with AR. This observational study using a very simple assessment tool (VAS) on a mobile phone had the potential to answer questions previously thought infeasible. © 2019 American Academy of Allergy, Asthma & Immunology
  • No Thumbnail Available
    Item
    Next-generation Allergic Rhinitis and Its Impact on Asthma (ARIA) guidelines for allergic rhinitis based on Grading of Recommendations Assessment, Development and Evaluation (GRADE) and real-world evidence
    (Mosby Inc., 2020) Bousquet J.; Schünemann H.J.; Togias A.; Bachert C.; Erhola M.; Hellings P.W.; Klimek L.; Pfaar O.; Wallace D.; Ansotegui I.; Agache I.; Bedbrook A.; Bergmann K.-C.; Bewick M.; Bonniaud P.; Bosnic-Anticevich S.; Bossé I.; Bouchard J.; Boulet L.-P.; Brozek J.; Brusselle G.; Calderon M.A.; Canonica W.G.; Caraballo L.; Cardona V.; Casale T.; Cecchi L.; Chu D.K.; Costa E.M.; Cruz A.A.; Czarlewski W.; D'Amato G.; Devillier P.; Dykewicz M.; Ebisawa M.; Fauquert J.-L.; Fokkens W.J.; Fonseca J.A.; Fontaine J.-F.; Gemicioglu B.; van Wijk R.G.; Haahtela T.; Halken S.; Ierodiakonou D.; Iinuma T.; Ivancevich J.-C.; Jutel M.; Kaidashev I.; Khaitov M.; Kalayci O.; Kleine Tebbe J.; Kowalski M.L.; Kuna P.; Kvedariene V.; La Grutta S.; Larenas-Linnemann D.; Lau S.; Laune D.; Le L.; Lieberman P.; Lodrup Carlsen K.C.; Lourenço O.; Marien G.; Carreiro-Martins P.; Melén E.; Menditto E.; Neffen H.; Mercier G.; Mosgues R.; Mullol J.; Muraro A.; Namazova L.; Novellino E.; O'Hehir R.; Okamoto Y.; Ohta K.; Park H.S.; Panzner P.; Passalacqua G.; Pham-Thi N.; Price D.; Roberts G.; Roche N.; Rolland C.; Rosario N.; Ryan D.; Samolinski B.; Sanchez-Borges M.; Scadding G.K.; Shamji M.H.; Sheikh A.; Bom A.-M.T.; Toppila-Salmi S.; Tsiligianni I.; Valentin-Rostan M.; Valiulis A.; Valovirta E.; Ventura M.-T.; Walker S.; Waserman S.; Yorgancioglu A.; Zuberbier T.
    The selection of pharmacotherapy for patients with allergic rhinitis aims to control the disease and depends on many factors. Grading of Recommendations Assessment, Development and Evaluation (GRADE) guidelines have considerably improved the treatment of allergic rhinitis. However, there is an increasing trend toward use of real-world evidence to inform clinical practice, especially because randomized controlled trials are often limited with regard to the applicability of results. The Contre les Maladies Chroniques pour un Vieillissement Actif (MACVIA) algorithm has proposed an allergic rhinitis treatment by a consensus group. This simple algorithm can be used to step up or step down allergic rhinitis treatment. Next-generation guidelines for the pharmacologic treatment of allergic rhinitis were developed by using existing GRADE-based guidelines for the disease, real-world evidence provided by mobile technology, and additive studies (allergen chamber studies) to refine the MACVIA algorithm. © 2019 American Academy of Allergy, Asthma & Immunology
  • No Thumbnail Available
    Item
    Impact of Pregnancy and Glucocorticoid Treatment on NF-κB and MUC5AC in Mucosa of Rat Larynx
    (Mosby Inc., 2021) Ulkumen B.; Artunc Ulkumen B.; Batir M.B.; Pala H.G.; Vatansever S.; Cam S.
    Objective: The aim of this study is to reveal physiological expression and distribution of nuclear factor-kappa B (NF-κB) and MUC 5 subtype AC (MUC5AC) in rat laryngeal mucosa and to find out the effect of pregnancy and glucocorticoid treatment on these biomolecules. Methods: This animal experiment was done in Experimental Animals Research and Application Center of Manisa Celal Bayar University in accordance with the accepted policy on the use of animals. A total of 30 young, adult Wister albino female rats were randomized into a control group (group A), a pregnant group (group B), and a steroid administered group (group C). Sacrification was done by injection of sodium-pentobarbitone (400 mg/kg) solution via intraperitoneal route in all groups. Serum estradiole (E2) and progesterone (PG) were determined by enzyme-linked immunosorbent assay. The relative expression and distribution of NF-κB and MUC5AC in laryngeal mucosa was studied both by immunohistochemistry (IHC) and polymerase chain reaction testing. Expression and immunohistochemical localization of NF-κB and MUC5AC was evaluated by light microscopy (Olympus BX41). In statistical analyses; relative expression of NF-κB and MUC5AC were compared on group basis. The effect of E2 and PG levels on these biomolecules was also evaluated. Results: NF-κB was found to be significantly low both in group B (P < 0.05) and C (P < 0.001) when compared with group A, while MUC5AC was found to be significantly high both in group B (P < 0.05) and group C (P < 0.05) when compared with group A. Concerning IHC; NF-κB was found to be expressed in epithelium and lamina propria. MUC5AC was found to be expressed particularly in the epithelial layer in all groups. Statistically significant negative correlation between PG and NF-κB expression (P = 0.048), but no correlation between PG and MUC5AC expression (P = 0.487) were revealed. On the other hand, no correlation was found between E2 and the expression of relevant biomolecules (NF-κB [P = 0.270], MUC5AC [P = 0.829]). We also did found a significant negative correlation between the expression of NF-κB and MUC5AC (P = 0.031). Conclusions: In this study, the physiological expression of NF-κB and MUC5AC in rat laryngeal mucosa was shown for the first time both by polymerase chain reaction and IHC. The impact of pregnancy and glucocorticoid treatment on the expression and distribution of these biomolecules was also revealed. The expression of NF-κB was found to be decreased while the expression of MUC5AC was found to be increased both by pregnancy and glucocorticoid treatment. The inhibitory effect of serum PG on NF-κB expression in rat laryngeal mucosa was also shown for the first time. The expression of MUC5AC was found to be increased both in pregnant and glucocorticoid administered group. Negative correlation between NF-κB and MUC5AC expression was also revealed in rat larynx for the first time. These findings may partially unclose the histochemical background of voice changes caused by pregnancy and as well as by glucocorticoid treatment. © 2019 The Voice Foundation